Beckley Psytech

Beckley Psytech is now part of AtaiBeckley, a global leader in transformative mental health therapies.

[Beckley Psytech @BeckleyPsytech]

We’re thrilled to announce that, following our strategic combination with atai Life Sciences, Beckley Psytech is now part of AtaiBeckley, a global leader in transformative mental health therapies. Follow us at @ataibeckley and on our website: https://t.co/tw46dizUPp.

[AtaiBeckley Inc @ataibeckley]

#News: We’re thrilled to announce the successful completion of atai Life Sciences’ strategic combination with Beckley Psytech. Together, we are now AtaiBeckley, a global leader in transformative mental health therapies.
Read the press release here: https://t.co/24ocDeRcyp

[Beckley Psytech @BeckleyPsytech]

We're looking forward to sharing data on BPL-003 and SSRIs at the CNS Summit in Boston next week.

Make sure to drop by to learn more.

https://t.co/xoTOiyuNEL

[Beckley Psytech @BeckleyPsytech]

[FOR INVESTORS AND MEDIA] The FDA has granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression. This milestone validates our strong Phase 2b data and accelerates our path forwards to Phase 3.

https://t.co/yCzoCiSn7I

[Beckley Psytech @BeckleyPsytech]

We are excited to present data on BPL-003 and anhedonia at ECNP this weekend. Make sure to swing by to learn more!

https://t.co/lrbixMgGAl

[Beckley Psytech @BeckleyPsytech]

We’re proud to share clinical data from our open-label Phase 2a study of BPL-003 in patients with treatment-resistant depression (TRD), investigating the effects of a two-dose induction regimen.

Read more here: https://t.co/sCUwGyMYkE

[Beckley Psytech @BeckleyPsytech]

Our CEO & Co-Founder, Cosmo Feilding Mellen, joined @Labiotech_eu’s Beyond Biotech podcast to discuss how next-gen psychedelics could help patients with treatment-resistant depression.

Listen here https://t.co/zFlmGooBFA

#MentalHealth #Psychedelics #Biotech

[Christian Angermayer @C_Angermayer]

Today, $ATAI announced outstanding Phase 2b data for BPL-003 (5-MeO-DMT).

In parallel, core shareholders – including myself and pharma company @ferring – demonstrated conviction by investing $50 million together with top-tier biotech funds.

I firmly believe psychedelics have the potential to heal millions and fundamentally transform mental health treatment. In doing so, they will make a deep, positive dent in the universe. Especially in the times ahead, we humans need psychedelics more than ever.

My hope is for @atai_life to lead this revolution – scientifically, commercially, and spiritually.

atai is the greatest entrepreneurial endeavour of my life, and I believe it will yield rich returns – both financial and emotional – for everyone involved.

Check out my latest blog post:
https://t.co/hWrBss9BZi

[Beckley Psytech @BeckleyPsytech]

Breaking: Positive topline data from our Phase 2b study of BPL-003 in treatment-resistant depression.

A key step toward Phase 3 and our mission to deliver faster, longer-lasting psychedelic treatments to those who need them most.

https://t.co/P3P2SBithc

[Beckley Psytech @BeckleyPsytech]

We’re proud to join @MentalHealthAm's Regional Policy Council - a national network shaping mental health policy through lived experience, collaboration and innovation.

Together, we aim to ensure emerging treatments lead to real-world impact.

[Beckley Psytech @BeckleyPsytech]

Prof. John Marsden (King’s College London) and Dr. Anya Ermakova (Beckley Psytech) will be sharing novel clinical and micro-phenomenological data from our Phase IIa study of BPL-003 for Alcohol Use Disorder at the 2025 CPDD Annual Meeting.

🔗 Learn more: https://t.co/72xtUK1mbx

[Beckley Psytech @BeckleyPsytech]

NEWS: Beckley Psytech and @atai_life ($ATAI) to combine to form a global leader in psychedelic mental health therapies.

Together, we’re accelerating innovation for those in need.

Learn more: https://t.co/byIoBIdeW6

[Beckley Psytech @BeckleyPsytech]

Today we announced positive topline results from our Phase IIa study of BPL-003 in combination with SSRIs for treatment resistant depression.

Read more on our website: https://t.co/9HRVOjIZVH

[Beckley Psytech @BeckleyPsytech]

We will be presenting data from our Phase IIa study of BPL-003 for TRD at #SOBP2025 in Toronto tomorrow at 5pm EDT. Looking forward to connecting with the scientific community.

https://t.co/htcP4Zewrr

[Beckley Psytech @BeckleyPsytech]

It's Brain Awareness Week - the perfect time to highlight the first-of-its-kind brain imaging study going on at @imperialcollege with BPL-003.

Check out our Q&A with the experts behind the study (@neurodelia, @tommaso_barba) below.

[Beckley Psytech @BeckleyPsytech]

We have completed enrolment in the core stage of our Phase IIb study of BPL-003 for Treatment Resistant Depression. Grateful to our trial participants & partners who made this study happen! https://t.co/yNWbkT8YzX

[Beckley Psytech @BeckleyPsytech]

Today is International Day of Women and Girls in Science! 🌍🔬 At Beckley Psytech, we’re celebrating the brilliant women in our team who are shaping the future of science. Hear about some of their experiences below. #IDWGS #WomenInSTEM

[Beckley Psytech @BeckleyPsytech]

Topline data from our Phase IIa study of BPL-003 for Alcohol Use Disorder show that a single dose was well-tolerated and delivered a meaningful and sustained reduction in alcohol use and Heavy Drinking Days over a 3-month evaluation period.
https://t.co/Ixyh7TQD69

[Beckley Psytech @BeckleyPsytech]

Initial findings from our Phase IIa study of ELE-101 for depression shows that a single 10-minute infusion is well-tolerated, induces rapid and lasting antidepressant effects, and allows patients to be ready for discharge in ~2 hours. Read more here: https://t.co/3EhGYwuUzz

[Beckley Psytech @BeckleyPsytech]

🎙️ In this fascinating episode of @healthtechpod with @JamesSomauroo, our CEO, Cosmo Feilding Mellen, shares his insights on psychedelics, consciousness, and mental health innovation.

🎧 Listen here: https://t.co/SVIjSfn0gs

[Beckley Psytech @BeckleyPsytech]

ICYMI: Our CEO, Cosmo Feilding Mellen, caught up with @TIME to discuss how our novel short-acting, psychedelic-based therapies could revolutionise the treatment of mental health conditions.

Learn more here: https://t.co/HFwwlJoWwr